Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19: Serologic Testing (September 2020)
Background The availability of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2) serologic testing has rapidly increased. Current assays use a variety of technologies …
2) serologic testing has rapidly increased. Current assays use a variety of technologies …
[HTML][HTML] Safety and efficacy of convalescent plasma combined with other pharmaceutical agents for treatment of COVID-19 in hospitalized patients: a systematic …
Plasma collected from people recovered from COVID-19 (COVID-19 convalescent plasma,
CCP) was the first antibody-based therapy employed to fight the pandemic. CCP was …
CCP) was the first antibody-based therapy employed to fight the pandemic. CCP was …
COVID‐19 after hematopoietic cell transplantation and chimeric antigen receptor (CAR)‐T‐cell therapy
More than 3 years have passed since Coronavirus disease 2019 (COVID‐19) was declared
a global pandemic, yet COVID‐19 still severely impacts immunocompromised individuals …
a global pandemic, yet COVID‐19 still severely impacts immunocompromised individuals …
Efficacy of combined COVID-19 convalescent plasma with oral RNA-dependent RNA polymerase inhibitor treatment versus neutralizing monoclonal antibody therapy …
T Siripongboonsitti, N Nontawong… - Microbiology …, 2023 - Am Soc Microbiol
The effectiveness of neutralizing monoclonal antibodies against emerging variants with
spike protein mutations has been limited. Early high-titer convalescent plasma therapy …
spike protein mutations has been limited. Early high-titer convalescent plasma therapy …
[HTML][HTML] Hyperimmune Plasma and Immunoglobulins against COVID-19: a narrative review
M Franchini, D Focosi - Life, 2024 - mdpi.com
Since late 2019, the new SARS-CoV-2 virus belonging to the Coronaviridae family has been
responsible for COVID-19 pandemic, a severe acute respiratory syndrome. Several antiviral …
responsible for COVID-19 pandemic, a severe acute respiratory syndrome. Several antiviral …
Executive summary of the consensus statement of the group for the study of infection in transplantation and other immunocompromised host (GESITRA-IC) of the …
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) arose in December 2019
in China rapidly evolving to the Coronavirus Disease 2019 (COVID-19) pandemic. Since …
in China rapidly evolving to the Coronavirus Disease 2019 (COVID-19) pandemic. Since …
The value of observational registry studies for the next infectious disease emergency
During infectious disease emergencies, it may be necessary to deploy new therapies
without conclusive evidence for their effectiveness. During the SARS-CoV-2 pandemic …
without conclusive evidence for their effectiveness. During the SARS-CoV-2 pandemic …
Report of consensus panel 5 from the 11th international workshop on Waldenstrom's macroglobulinemia on COVID-19 prophylaxis and management
Abstract Consensus Panel 5 (CP5) of the 11th International Workshop on Waldenstrom's
Macroglobulinemia (IWWM-11; held in October 2022) was tasked with reviewing the current …
Macroglobulinemia (IWWM-11; held in October 2022) was tasked with reviewing the current …
COVID-19 convalescent plasma retains value for immunocompromised patients
D Focosi, M Franchini - Leukemia, 2023 - nature.com
We read with interest the recent review by Terpos et al. on management of COVID-19 in
multiple myeloma (MM) patients. We disagree with some of the authors recommendations …
multiple myeloma (MM) patients. We disagree with some of the authors recommendations …
Neutralizing anti-spike monoclonal antibodies for COVID-19 in vulnerable populations: lessons learned and future directions
RR Razonable - Expert Opinion on Biological Therapy, 2023 - Taylor & Francis
Introduction Anti-spike monoclonal antibodies were highly effective for prophylaxis and early
treatment of mild-to-moderate COVID-19 in high-risk populations. Areas covered This article …
treatment of mild-to-moderate COVID-19 in high-risk populations. Areas covered This article …